Free Trial
NYSE:LLY

Eli Lilly and Company Q2 2025 Earnings Report

Eli Lilly and Company logo
$761.47 +21.40 (+2.89%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$761.75 +0.28 (+0.04%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company EPS Results

Actual EPS
N/A
Consensus EPS
$5.56
Beat/Miss
N/A
One Year Ago EPS
N/A

Eli Lilly and Company Revenue Results

Actual Revenue
N/A
Expected Revenue
$14.40 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eli Lilly and Company Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
10:00AM ET

Conference Call Resources

Eli Lilly and Company Earnings Headlines

Blue poker chips next to a blue piggy bank
Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season (LLY)
These 3 blue-chip stocks offer strong earnings power and growth opportunities as uncertainty lingers in the second half of 2025...
3 Unstoppable Stocks to Buy in August
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.
Trim Your AI Stocks And Buy Eli Lilly
Eli Lilly: The Best Growth Prospects Come At A Price
See More Eli Lilly and Company Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eli Lilly and Company? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eli Lilly and Company and other key companies, straight to your email.

About Eli Lilly and Company

Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

View Eli Lilly and Company Profile

More Earnings Resources from MarketBeat